4
1
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T82022 | IVMT-Rx-3 | NF-κB | |
IVMT-Rx-3 is a chemical compound that serves as an inhibitor of SDCBP's targeting of the PDZ1 and PDZ2 domains of MDA-9/Syntenin. It effectively blocks the MDA-9/Syntenin-Src interaction, diminishes NF-κB activation, and... | |||
T73541 | SYNTi | ||
SYNTi, a PDZ domain inhibitor, specifically targets the syndecan/syntenin protein-protein interaction, demonstrating an IC50 of 400 nM and a ligand efficiency (LE) value of 0.24. It holds potential for use in breast canc... | |||
T63797 | PDZ1i | ||
PDZ1i is a potent MDA-9/Syntenin-specific inhibitor that crosses the blood-brain barrier. PDZ1i inhibits key GBM (glioblastoma multiforme) signaling, including FAK and EGFRvIII, and reduces MMP secretion. | |||
T83716 | KSL-128114 TFA | Ac-rRrGrKkRrSHWX1X2DI-OH (X1=tert-Leucine; X2=Cyclohexylglycine) | |
KSL-128114, a peptide inhibitor of the membrane regulator syntenin (Ki = 300 nM), notably diminishes the viability of A2058 melanoma and patient-derived glioblastoma multiforme (GBM) cells in a concentration-dependent ma... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04817 | Syntenin Protein, Human, Recombinant (His) | Human | E. coli |
Syntenin1/SDCBP (syndecan binding protein), also known as melanoma differentiation associated gene-9 (MDA-9), is a PDZ domain-containing molecule, which was initially identified as a key oncogene in melanoma. IL-6 promot... |